OBJECTIVE: To identify components of a provisional clinical response index for thyroid eye disease using a modified Delphi technique. METHODS: The International Thyroid Eye Disease Society conducted a structured, 3-round Delphi exercise establishing consensus for a core set of measures for clinical trials in thyroid eye disease. The steering committee discussed the results in a face-to-face meeting (nominal group technique) and evaluated each criterion with respect to its feasibility, reliability, redundancy, and validity. Redundant measures were consolidated or excluded. RESULTS: Criteria were parsed into 11 domains for the Delphi surveys. Eighty-four respondents participated in the Delphi 1 survey, providing 220 unique items. Ninety-two members (100% of the respondents from Delphi 1 plus 8 new participants) responded in Delphi 2 and rated the same 220 items. Sixty-four members (76% of participants) rated 153 criteria in Delphi 3 (67 criteria were excluded because of redundancy). Criteria with a mean greater than 6 (1 = least appropriate to 9 = most appropriate) were further evaluated by the nominal group technique and provisional core measures were chosen. CONCLUSIONS: Using a Delphi exercise, we developed provisional core measures for assessing disease activity and severity in clinical trials of therapies for thyroid eye disease. These measures will be iteratively refined for use in multicenter clinical trials.
OBJECTIVE: To identify components of a provisional clinical response index for thyroid eye disease using a modified Delphi technique. METHODS: The International Thyroid Eye Disease Society conducted a structured, 3-round Delphi exercise establishing consensus for a core set of measures for clinical trials in thyroid eye disease. The steering committee discussed the results in a face-to-face meeting (nominal group technique) and evaluated each criterion with respect to its feasibility, reliability, redundancy, and validity. Redundant measures were consolidated or excluded. RESULTS: Criteria were parsed into 11 domains for the Delphi surveys. Eighty-four respondents participated in the Delphi 1 survey, providing 220 unique items. Ninety-two members (100% of the respondents from Delphi 1 plus 8 new participants) responded in Delphi 2 and rated the same 220 items. Sixty-four members (76% of participants) rated 153 criteria in Delphi 3 (67 criteria were excluded because of redundancy). Criteria with a mean greater than 6 (1 = least appropriate to 9 = most appropriate) were further evaluated by the nominal group technique and provisional core measures were chosen. CONCLUSIONS: Using a Delphi exercise, we developed provisional core measures for assessing disease activity and severity in clinical trials of therapies for thyroid eye disease. These measures will be iteratively refined for use in multicenter clinical trials.
Authors: Mark F Prummel; Annemieke Bakker; Wilmar M Wiersinga; Lelio Baldeschi; Maarten P Mourits; Pat Kendall-Taylor; Petros Perros; Chris Neoh; A Jane Dickinson; John H Lazarus; Carol M Lane; Armin E Heufelder; George J Kahaly; Suzanne Pitz; Jacques Orgiazzi; Alain Hullo; Aldo Pinchera; Claudio Marcocci; Maria S Sartini; Roberto Rocchi; Marco Nardi; Gerry E Krassas; A Halkias Journal: Eur J Endocrinol Date: 2003-05 Impact factor: 6.664
Authors: J Braun; T Pham; J Sieper; J Davis; Sj van der Linden; M Dougados; D van der Heijde Journal: Ann Rheum Dis Date: 2003-09 Impact factor: 19.103
Authors: N Bellamy; T P Anastassiades; W W Buchanan; P Davis; P Lee; G A McCain; G A Wells; J Campbell Journal: J Rheumatol Date: 1991-12 Impact factor: 4.666
Authors: N Bellamy; W W Buchanan; J M Esdaile; A G Fam; W F Kean; J M Thompson; G A Wells; J Campbell Journal: J Rheumatol Date: 1991-11 Impact factor: 4.666
Authors: Kevan C Herold; Stephen E Gitelman; Umesh Masharani; William Hagopian; Brygida Bisikirska; David Donaldson; Kristina Rother; Beverly Diamond; David M Harlan; Jeffrey A Bluestone Journal: Diabetes Date: 2005-06 Impact factor: 9.461
Authors: Ian J Saldanha; Kristina Lindsley; Diana V Do; Roy S Chuck; Catherine Meyerle; Leslie S Jones; Anne L Coleman; Henry D Jampel; Kay Dickersin; Gianni Virgili Journal: JAMA Ophthalmol Date: 2017-09-01 Impact factor: 7.389
Authors: Samera Dean; Jonathan M Mathers; Melanie Calvert; Derek G Kyte; Dolores Conroy; Annie Folkard; Sue Southworth; Philip I Murray; Alastair K Denniston Journal: Br J Ophthalmol Date: 2017-04-28 Impact factor: 4.638